The combination of nivolumab and low-dose ipilimumab demonstrated a superior benefit in terms of OS compared to chemotherapy in first-line NSCLC patients whose tumors express PD-L1 ≥1% [39]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.